Abstract:In this case report, we describe the case of an asymptomatic adult female who was found to have a new variant of unknown significance, p.Met70Val. Given the unknown pathogenic role of this variant, a thorough analysis of the potential organ involvement was conducted. The analysis revealed that there were no signs of significant organ involvement, and the benignity of the mutation was confirmed. This case underscores the importance of a comprehensive evaluation of new variants of unknown significance to establish their pathogenicity accurately. Background Fabry disease (FD) is a rare X‐linked lysosomal storage disorder caused by variants in GLA gene leading to deficient α‐galactosidase A enzyme activity. This deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), in various tissues and organs, which can result in life‐threatening complications. The clinical presentation of the disease can vary from the "classic" phenotype with pediatric onset and multi‐organ involvement to the "later‐onset" phenotype, which presents with predominantly cardiac symptoms. In recent years, advances in screening studies have led to the identification of an increasing number of variants of unknown significance that have not yet been described, and whose pathogenic role remains undetermined. Methods In this clinical report, we describe the case of an asymptomatic adult female who was found to have a new variant of unknown significance, p.Met70Val. Given the unknown pathogenic role of this variant, a thorough analysis of the potential organ involvement was conducted. The clinical data were analyzed retrospectively. Results The analysis revealed that there were no signs of significant organ involvement, and the benignity of the variant was confirmed. Conclusion This case underscores the importance of a comprehensive evaluation of new variants of unknown significance to establish their pathogenicity accurately.

Mild Left Ventricular Hypertrophy Unravels a Novel Nonsense Mutation of the GLA Gene Associated with the Classical Phenotype of Fabry Disease

Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family

Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis

Previously Unidentified Gene Variation Associated with Fabry Disease: The Impact on One Family

c.640–814 T > C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect

Novel GLA gene mutations in two Chinese families with classic Fabry disease

No evidence of Fabry disease in a patient with the new p.Met70Val GLA gene variant

Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report

Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations

Fabry disease caused by the GLA p.Gly183Asp (p.G183D) variant: Clinical profile of a serious phenotype

Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients with Fabry Disease and IVS4 + 919g>a GLA Mutation is Progressive with Age and Correlates with Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection Fraction

The c.‐265G>A GLA gene promoter variant causes Fabry disease: The hidden culprit identified

GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease

A Female Patient of Fabry Disease Complicated with Thin Basement Membrane Nephropathy and Investigation of the Kindred

Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy

Fabry Disease: A Atypical Presentation

Prognostic Implications of Left Ventricular Hypertrophy and Mechanical Function in Fabry Disease: A Longitudinal Cohort Study

Endomyocardial Biopsies in Patients with Left Ventricular Hypertrophy and a Common Chinese Later-Onset Fabry Mutation (IVS4 + 919G > A)

Genotype–Phenotype Spectrum of 52 Mexican Patients With Fabry Disease: A Novel GLA Variant With Atypical Phenotype

Biomarkers Associated with Clinical Manifestations in Fabry Disease Patients with a Late-Onset Cardiac Variant Mutation.

Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C